logo-loader

Nuformix team up with Oxilio to accelerate NXP001 oncology asset development

Published: 15:11 16 Sep 2021 BST

Nuformix PLC (LSE:NFX, FRA:1RT) (LSE:NFX, FRA:1RT) chief executive Dr Anne Brindley joins Proactive to explain the significance of signing an exclusive global licensing agreement for NXP001, an oncology drug candidate.

The company has licensed NXP001 to a privately owned company, Oxilio Ltd, which will research, develop and commercialise NXP001 globally for oncology indications.

Brindley explains how the company is delighted as the deal is a major step forward as it validates the Nuformix technology and intellectual property, and also endorses the strategy of repurposing drugs and licensing at an early stage.

Brindley also explains her decision to depart the company in January and the company's replacement plans for the CEO position.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

1 hour, 48 minutes ago